Tadalafil tablets recalled due to manufacturing process deviations
Accord Healthcare is recalling Tadalafil 2.5 mg tablets following discovery of manufacturing deviations during an FDA inspection. Approximately 36,773 bottles were distributed in the United States, Puerto Rico, and Canada.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class II recall involving manufacturing process deviations with no reported illnesses or injuries. Per the severity rubric, Class II recalls without hospitalization reports and with theoretical hazards score 2 (Moderate).
Plain-English summary
Accord Healthcare, Inc. is recalling Tadalafil Tablets, USP, 2.5 mg due to manufacturing deviations discovered during an FDA inspection. The affected medication is supplied in 30-count and 500-count bottles with varying batch codes. Approximately 36,773 bottles have been distributed across the United States, including Puerto Rico, and Canada.
The recall was initiated following identification of Current Good Manufacturing Practice (CGMP) deviations. The specific nature of these deviations is not detailed in the recall notice.
Consumers with this medication should contact their healthcare provider or pharmacist for guidance. For specific product information including affected batch numbers and NDC codes, consumers may contact the FDA or Accord Healthcare.
The recalled product
- Product
- TADALAFIL (TADALAFIL)
- Brand
- TADALAFIL
- Manufacturer
- Accord Healthcare, Inc.
- Category
- Drug — Oral tablet
- Hazard
- Affected units
- 36,773
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (16)
- Batches: a) P2002522
- Exp. Date 4/30/2023
- P2005817
- P2005816
- Exp. Date 10/31/2023
- P2203687
- Exp. Date 6/30/2025
- b) P2002521
- P2005818
- P2100075
- Exp. Date 12/31/2023
- P2100996
- P2100997
- P2100998
- P2100999
- Exp. Date 1/31/2024
UPCs (5)
- 0316729372107
- 0316729369107
- 0316729370103
- 316729369107
- 316729369169
Distribution
Distributed in 1 state:
Part of a larger recall action
This product is one of 67 recalled by Accord Healthcare, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 67 products in this recall →Related recalls
Same brand · TADALAFIL
- HighTadalafil Tablets Recalled Due to Manufacturing Practice Violations
FDA (Drugs) · 2023-05-03
- ModerateTadalafil Tablets 20 mg recalled due to manufacturing deviations
FDA (Drugs) · 2023-05-03
- ModeratePrescription Tadalafil tablets recalled for manufacturing process deviations
FDA (Drugs) · 2023-04-12
- HighFDA Recalls Tadalafil Tablets Due to Manufacturing Practice Deviations
FDA (Drugs) · 2023-03-08
- HighTadalafil Tablets Recalled Due to Manufacturing Practice Deviations
FDA (Drugs) · 2023-03-08
Same manufacturer · Accord Healthcare, Inc.
See all →- SevereAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- HighAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- SevereAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- HighAccord Healthcare Recalls Subpotent Levothyroxine Sodium Tablets
FDA (Drugs) · 2026-09-02
- SevereAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
Same hazard · manufacturing defect
See all →- HighBeak & Skiff Alcohol Antiseptic Sanitizer recalled for acetaldehyde contamination
FDA (Drugs) · 2026-09-02
- HighSun Pharmaceutical Recalls Carbamazepine Tablets Due to Manufacturing Deviations
FDA (Drugs) · 2026-08-26
- HighU2 Total Knee System Femoral Valgus Adaptor Recall
FDA (Devices) · 2026-08-12
- HighUnited Orthopedic Corp. Recalls Femoral Valgus Offset Adaptors for U2 Total Knee System
FDA (Devices) · 2026-08-12
- HighKnee Prosthesis Trial Recall for Manufacturing Defect
FDA (Devices) · 2026-08-12